Aug 20, 2025 • Zacks Commentary
BULLISH
DexCom Expands Access and Innovation While Balancing Headwinds
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
Aug 20, 2025 • CNBC
NEUTRAL
FDA approves first-ever glucose monitoring system for weight loss from Signos
Any patient can access Signos' system, which uses an AI platform and an off-the-shelf continuous glucose monitor, or CGM, from Dexcom.
Aug 16, 2025 • Motley Fool
SOMEWHAT-BULLISH
2 Stocks to Buy on the Dip and Hold for 10 Years
There should be plenty of long-term upside for these stocks for investors willing to ride out the storm.
Aug 15, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
Aug 07, 2025 • Motley Fool
BULLISH
Insulet ( PODD ) Q2 Revenue Jumps 33%
Insulet ( NASDAQ:PODD ) , a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong outperformance: GAAP revenue rose to $649.1 million, beating estimates by nearly $35 million, while ...
Aug 07, 2025 • Benzinga
NEUTRAL
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - DexCom ( NASDAQ:DXCM )
NEW YORK, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc.